Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug2925 | SOC Wiki | 0.71 |
drug3046 | Silmitasertib Wiki | 0.71 |
Name (Synonyms) | Correlation | |
---|---|---|
D059246 | Tachypnea NIH | 1.00 |
D000860 | Hypoxia NIH | 0.19 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0002789 | Tachypnea HPO | 1.00 |
HP:0012418 | Hypoxemia HPO | 0.19 |
Navigate: Correlations HPO
There is one clinical trial.
The study is an unblinded, randomized, controlled trial for use of the AirFlO2 device for patients admitted to Duke Hospital with COVID-19 and tachypnea (RR >20 breaths/min) and/or hypoxia (Oxygen saturation <94% on room air or requiring supplemental oxygen at baseline).
Description: Improve hypoxia as measured by change between baseline P:F ratio and repeat P:F ratio inspired oxygen- P:F ratio (PaO2:FiO2), a higher value indicates better oxygenation. Range 20 to 500.
Measure: Improve hypoxia as measured by change between baseline P:F ratio and repeat P:F ratio Time: change from baseline compared to one to six hours after initial device interventionDescription: Improved symptoms related to dyspnea as measured by the change in the Modified Medical Research Council (MMRC).. Range 0 to 4 with lower values being better.
Measure: Subject dyspnea symptoms Time: baseline to end of hospitalization, (discharge from hospital or death, 1 - 30 days range)Description: Improved symptoms related to cough as measured by the change in Leicester Cough Questionnaire (LCQ) questionnaire, score range 3-21, a higher score indicates better quality of life.
Measure: Subject cough symptoms Time: baseline to up to six hours for device intervention participants; baseline to hospital discharge (up to 30 days) for all patientsDescription: Improve subjective symptoms related to cough as measured by the change in St George Respiratory Questionnaire (SGRC) questionnaire, score range 0-100, a higher score indicates worse quality of life.
Measure: Subject respiratory symptoms Time: baseline to up to six hours for device intervention participants; baseline to hospital discharge (up to 30 days) for all patientsDescription: Reduce risk of respiratory deterioration as measured by change from baseline to end of hospitalization (discharge or patient death) to high flow nasal cannula (HFNC), non-invasive ventilation (NIV), or invasive ventilation
Measure: Reduced risk progression of respiratory deterioration Time: baseline to end of hospitalization, (discharge from hospital or death, 1 - 30 days range)Description: Reduced intensive care unit (ICU) transfer risk, as measured by a change from baseline to end of hospitalization of ICU admission.
Measure: Reduced risk of ICU transfer Time: baseline to end of hospitalization, (discharge from hospital or death, 1 - 30 days range)Description: Reduce risk for intubation requirement as measured by incidence of intubation occurring between baseline and end of hospitalization (discharge or death)
Measure: Reduced risk for intubation Time: baseline to end of hospitalization, (discharge from hospital, or death, 1 - 30 days range)Description: Reduced hospitalization length of stay as measured by length of hospitalization after the baseline timepoint.
Measure: Reduced hospitalization length of stay Time: baseline to end of hospitalization, (discharge from hospital or death, 1 - 30 days range)Description: Increased patient survival to hospital discharge as measured by the participant status at the end of the hospitalization (discharge or death)
Measure: Increased patient survival to discharge Time: baseline to end of hospitalization, (discharge from hospital- 1 - 30 days expected range)Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports